{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:39:28Z","timestamp":1790213968165,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Orphalan Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40265-024-02099-0","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T15:03:08Z","timestamp":1729177388000},"page":"1509-1518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Trientine Tetrahydrochloride, From Bench to Bedside: A Narrative Review"],"prefix":"10.1007","volume":"84","author":[{"given":"C. Omar F.","family":"Kamlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"M. Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3585-7866","authenticated-orcid":false,"given":"Jamie","family":"L Heise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseem","family":"S. Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,17]]},"reference":[{"issue":"1","key":"2099_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41572-018-0018-3","volume":"4","author":"A Cz\u0142onkowska","year":"2018","unstructured":"Cz\u0142onkowska A, Litwin T, Dusek P, et al. Wilson disease. Nat Rev Dis Primers. 2018;4(1):21. https:\/\/doi.org\/10.1038\/s41572-018-0018-3.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"2099_CR2","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1002\/hep.32805","volume":"77","author":"ML Schilsky","year":"2023","unstructured":"Schilsky ML, Roberts EA, Bronstein JM, et al. A multidisciplinary approach to the diagnosis and management of Wilson disease: executive summary of the 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases. Hepatology. 2023;77(4):1428\u201355. https:\/\/doi.org\/10.1002\/hep.32805.","journal-title":"Hepatology"},{"issue":"9","key":"2099_CR3","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.3390\/ijms25094753","volume":"25","author":"R Teschke","year":"2024","unstructured":"Teschke R, Eickhoff A. Wilson disease: copper-mediated cuproptosis, iron-related ferroptosis, and clinical highlights, with comprehensive and critical analysis update. Int J Mol Sci. 2024;25(9):4753. https:\/\/doi.org\/10.3390\/ijms25094753.","journal-title":"Int J Mol Sci"},{"issue":"9559","key":"2099_CR4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(07)60196-2","volume":"369","author":"A Ala","year":"2007","unstructured":"Ala A, Walker AP, Ashkan K, et al. Wilson\u2019s disease. Lancet. 2007;369(9559):397\u2013408. https:\/\/doi.org\/10.1016\/S0140-6736(07)60196-2.","journal-title":"Lancet"},{"key":"2099_CR5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.7916\/D841881D","volume":"8","author":"A Aggarwal","year":"2018","unstructured":"Aggarwal A, Bhatt M. Advances in treatment of Wilson disease. Tremor Other Hyperkinet Mov (N Y). 2018;8:525. https:\/\/doi.org\/10.7916\/D841881D.","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"6","key":"2099_CR6","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1212\/wnl.59.6.914","volume":"59","author":"JA Vilensky","year":"2002","unstructured":"Vilensky JA, Robertson WM, Gilman S. Denny-Brown, Wilson\u2019s disease, and BAL (British antilewisite [2,3-dimercaptopropanol]). Neurology. 2002;59(6):914\u20136. https:\/\/doi.org\/10.1212\/wnl.59.6.914.","journal-title":"Neurology"},{"issue":"1","key":"2099_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1136\/gut.2005.087262","volume":"56","author":"U Merle","year":"2007","unstructured":"Merle U, Schaefer M, Ferenci P, Stremmel W. Clinical presentation, diagnosis and long-term outcome of Wilson\u2019s disease: a cohort study. Gut. 2007;56(1):115\u201320. https:\/\/doi.org\/10.1136\/gut.2005.087262.","journal-title":"Gut"},{"issue":"4","key":"2099_CR8","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1053\/j.gastro.2010.12.034","volume":"140","author":"KH Weiss","year":"2011","unstructured":"Weiss KH, Gotthardt DN, Klemm D, Merle U, Ferenci-Foerster D, Schaefer M, et al. Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease. Gastroenterology. 2011;140(4):1189-1198.e1. https:\/\/doi.org\/10.1053\/j.gastro.2010.12.034.","journal-title":"Gastroenterology"},{"issue":"6","key":"2099_CR9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/21678707.2019.1638248","volume":"7","author":"T Litwin","year":"2019","unstructured":"Litwin T, Dusek P, Skowro\u0144ska M, Cz\u0142onkowska A. Treatment of Wilson\u2019s disease: an update. Expert Opin Orphan Drugs. 2019;7(6):287\u201394. https:\/\/doi.org\/10.1080\/21678707.2019.1638248.","journal-title":"Expert Opin Orphan Drugs"},{"issue":"8","key":"2099_CR10","doi-asserted-by":"publisher","first-page":"732","DOI":"10.21037\/atm-20-3090","volume":"9","author":"W Stremmel","year":"2021","unstructured":"Stremmel W, Weiskirchen R. Therapeutic strategies in Wilson disease: pathophysiology and mode of action. Ann Transl Med. 2021;9(8):732. https:\/\/doi.org\/10.21037\/atm-20-3090.","journal-title":"Ann Transl Med"},{"issue":"1","key":"2099_CR11","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ijpharm.2016.06.140","volume":"511","author":"T Henriet","year":"2016","unstructured":"Henriet T, Gana I, Ghaddar C, Barrio M, Cartigny Y, Yagoubi N, et al. Solid state stability and solubility of triethylenetetramine dihydrochloride. Int J Pharm. 2016;511(1):312\u201321. https:\/\/doi.org\/10.1016\/j.ijpharm.2016.06.140.","journal-title":"Int J Pharm"},{"key":"2099_CR12","first-page":"1","volume":"12","author":"K Weigand","year":"2022","unstructured":"Weigand K, Corsini A. Specific pharmacokinetic features of two trientine preparations and their potential impact on treatment outcome. J Med Drug Rev. 2022;12:1\u20138.","journal-title":"J Med Drug Rev"},{"issue":"6","key":"2099_CR13","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/jimd.12430","volume":"44","author":"E Jacquelet","year":"2021","unstructured":"Jacquelet E, Poujois A, Pheulpin MC, et al. Adherence to treatment, a challenge even in treatable metabolic rare diseases: a cross sectional study of Wilson\u2019s disease. J Inherit Metab Dis. 2021;44(6):1481\u20138. https:\/\/doi.org\/10.1002\/jimd.12430.","journal-title":"J Inherit Metab Dis"},{"issue":"16","key":"2099_CR14","doi-asserted-by":"publisher","first-page":"9316","DOI":"10.3390\/ijms23169316","volume":"23","author":"A Avan","year":"2022","unstructured":"Avan A, Cz\u0142onkowska A, Gaskin S, Granzotto A, Sensi SL, Hoogenraad TU. The role of zinc in the treatment of Wilson\u2019s disease. Int J Mol Sci. 2022;23(16):9316. https:\/\/doi.org\/10.3390\/ijms23169316.","journal-title":"Int J Mol Sci"},{"issue":"14","key":"2099_CR15","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.3390\/jcm11143975","volume":"11","author":"F Woimant","year":"2022","unstructured":"Woimant F, Debray D, Morvan E, Obadia MA, Poujois A. Efficacy and safety of two salts of trientine in the treatment of Wilson\u2019s disease. J Clin Med. 2022;11(14):3975. https:\/\/doi.org\/10.3390\/jcm11143975.","journal-title":"J Clin Med"},{"key":"2099_CR16","doi-asserted-by":"crossref","unstructured":"Zuin M, Maggiore G, Loudianos G, et al. Voices of Italian patients with Wilson\u2019s disease: results from a quality survey. Poster presented at: International Liver Congress; 23\u201326 June, 2021; virtual: poster PO-1522.","DOI":"10.1016\/j.jval.2020.08.1850"},{"key":"2099_CR17","unstructured":"Morley et al. Patent No.: US 10,988,436 B2. Date of Patent: 27 April, 2021."},{"issue":"5","key":"2099_CR18","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s13318-021-00704-1","volume":"46","author":"KH Weiss","year":"2021","unstructured":"Weiss KH, Thompson C, Dogterom P, et al. Comparison of the pharmacokinetic profiles of trientine tetrahydrochloride and trientine dihydrochloride in healthy subjects. Eur J Drug Metab Pharmacokinet. 2021;46(5):665\u201375. https:\/\/doi.org\/10.1007\/s13318-021-00704-1.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"6","key":"2099_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000150","volume":"7","author":"N Alkhouri","year":"2023","unstructured":"Alkhouri N, Gonzalez-Peralta RP, Medici V. Wilson disease: a summary of the updated AASLD practice guidance. Hepatol Commun. 2023;7(6): e0150. https:\/\/doi.org\/10.1097\/HC9.0000000000000150.","journal-title":"Hepatol Commun"},{"issue":"5","key":"2099_CR20","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/HEP.0000000000000708","volume":"79","author":"FT Kirk","year":"2024","unstructured":"Kirk FT, Munk DE, Swenson ES, Quicquaro AM, Vendelbo MH, Schilsky ML, et al. Effects of trientine and penicillamine on intestinal copper uptake: a mechanistic 64 Cu PET\/CT study in healthy humans. Hepatology. 2024;79(5):1065\u201374. https:\/\/doi.org\/10.1097\/HEP.0000000000000708.","journal-title":"Hepatology"},{"issue":"4","key":"2099_CR21","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jhep.2023.11.023","volume":"80","author":"FT Kirk","year":"2024","unstructured":"Kirk FT, Munk DE, Swenson ES, et al. Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease. J Hepatol. 2024;80(4):586\u201395. https:\/\/doi.org\/10.1016\/j.jhep.2023.11.023.","journal-title":"J Hepatol"},{"issue":"3","key":"2099_CR22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/oxfordjournals.qjmed.a067346","volume":"42","author":"JM Walshe","year":"1973","unstructured":"Walshe JM. Copper chelation in patients with Wilson\u2019s disease: a comparison of penicillamine and triethylene tetramine dihydrochloride. Q J Med. 1973;42(3):441\u201352. https:\/\/doi.org\/10.1093\/oxfordjournals.qjmed.a067346.","journal-title":"Q J Med"},{"issue":"8","key":"2099_CR23","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1177\/0091270009337939","volume":"49","author":"HY Cho","year":"2009","unstructured":"Cho HY, Blum RA, Sunderland T, et al. Pharmacokinetic and pharmacodynamic modeling of a copper-selective chelator (TETA) in healthy adults. J Clin Pharmacol. 2009;49(8):916\u201328. https:\/\/doi.org\/10.1177\/0091270009337939.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"2099_CR24","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1177\/0091270009349379","volume":"50","author":"J Lu","year":"2010","unstructured":"Lu J, Poppitt SD, Othman AA, et al. Pharmacokinetics, pharmacodynamics, and metabolism of triethylenetetramine in healthy human participants: an open-label trial. J Clin Pharmacol. 2010;50(6):647\u201358. https:\/\/doi.org\/10.1177\/0091270009349379.","journal-title":"J Clin Pharmacol"},{"key":"2099_CR25","unstructured":"European Medicines Agency. CHMP assessment report. Cuprior\u00ae. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/cuprior-epar-public-assessment-report_en.pdf. Accessed Apr 2024."},{"issue":"9","key":"2099_CR26","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1158\/1535-7163.MCT-10-0523","volume":"9","author":"J Lu","year":"2010","unstructured":"Lu J. Triethylenetetramine pharmacology and its clinical applications. Mol Cancer Ther. 2010;9(9):2458\u201367. https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-0523.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"2099_CR27","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/j.1600-0404.1991.tb03964.x","volume":"83","author":"R Siegemund","year":"1991","unstructured":"Siegemund R, L\u00f6ssner J, G\u00fcnther K, K\u00fchn HJ, Bachmann H. Mode of action of triethylenetetramine dihydrochloride on copper metabolism in Wilson\u2019s disease. Acta Neurol Scand. 1991;83(6):364\u20136. https:\/\/doi.org\/10.1111\/j.1600-0404.1991.tb03964.x.","journal-title":"Acta Neurol Scand"},{"key":"2099_CR28","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00216-021-03517-y","volume":"414","author":"ME del Castillo Busto","year":"2022","unstructured":"del Castillo Busto ME, Cuello-Nunez S, Ward-Deitrich C, Morley T, Goenaga-Infante H. A fit-for-purpose copper speciation method for the determination of exchangeable copper relevant to Wilson\u2019s disease. Anal Bioanal Chem. 2022;414:561\u201373. https:\/\/doi.org\/10.1007\/s00216-021-03517-y.","journal-title":"Anal Bioanal Chem"},{"issue":"23\u201324","key":"2099_CR29","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.cca.2011.08.019","volume":"412","author":"S El Balkhi","year":"2011","unstructured":"El Balkhi S, Trocello JM, Poupon J, et al. Relative exchangeable copper: a new highly sensitive and highly specific biomarker for Wilson\u2019s disease diagnosis. Clin Chim Acta. 2011;412(23\u201324):2254\u201360. https:\/\/doi.org\/10.1016\/j.cca.2011.08.019.","journal-title":"Clin Chim Acta"},{"issue":"12","key":"2099_CR30","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/S2468-1253(22)00270-9","volume":"7","author":"ML Schilsky","year":"2022","unstructured":"Schilsky ML, Czlonkowska A, Zuin M, et al. Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomized, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2022;7(12):1092\u2013102. https:\/\/doi.org\/10.1016\/S2468-1253(22)00270-9.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"2099_CR31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jtemb.2007.11.001","volume":"22","author":"PJ Twomey","year":"2008","unstructured":"Twomey PJ, Viljoen A, Reynolds TM, Wierzbicki AS. Non-ceruloplasmin-bound copper in routine clinical practice in different laboratories. J Trace Elem Med Biol. 2008;22(1):50\u20133. https:\/\/doi.org\/10.1016\/j.jtemb.2007.11.001.","journal-title":"J Trace Elem Med Biol"},{"issue":"12","key":"2099_CR32","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/S2468-1253(22)00284-9","volume":"7","author":"V Medici","year":"2022","unstructured":"Medici V, Heffern MC. Monitoring and treatment of Wilson disease: progress and challenges. Lancet Gastroenterol Hepatol. 2022;7(12):1063\u20135. https:\/\/doi.org\/10.1016\/S2468-1253(22)00284-9.","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02099-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02099-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02099-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T02:23:22Z","timestamp":1736735002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02099-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2099"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02099-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,17]]},"assertion":[{"value":"16 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"C. Omar F. Kamlin, Timothy\u00a0M. Jenkins, Jamie\u00a0L. Heise, and Naseem S.\u00a0Amin are all employees of Orphalan Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the study conception and design. The first draft of the manuscript was written by Carol Ogg, BS Pharm. Critical review and revisions of the manuscript: JH, TJ, COFK, NA. All authors commented on previous versions of the manuscript. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}